Ghrelin improves endothelial function in patients with metabolic syndrome

Area of Science:

• Cardiovascular Science
• Endocrinology
• Metabolic Disorders

Background:

• Metabolic syndrome accelerates atherosclerosis, beginning with endothelial dysfunction.
• Ghrelin, a peptide hormone, exhibits cardiovascular effects and may inhibit proatherogenic changes.
• This study explored ghrelin's impact on endothelial function in metabolic syndrome.

Purpose of the Study:

• To investigate the effect of ghrelin administration on endothelial function in patients with metabolic syndrome.
• To determine if ghrelin can reverse endothelial dysfunction associated with metabolic syndrome.

Main Methods:

• Assessed endothelium-dependent (acetylcholine) and -independent (SNP) vasodilator responses using strain-gauge plethysmography.
• Measured responses before and after local ghrelin infusion in patients with metabolic syndrome and controls.
• Measured basal plasma ghrelin levels and nitric oxide bioavailability.

Main Results:

• Patients with metabolic syndrome showed blunted acetylcholine vasodilator responses compared to controls.
• Basal plasma ghrelin levels were lower in metabolic syndrome patients.
• Ghrelin infusion potentiated acetylcholine responses in metabolic syndrome patients, indicating improved endothelial function.
• This improvement was linked to enhanced nitric oxide bioavailability.

Conclusions:

• Ghrelin administration reverses endothelial dysfunction in metabolic syndrome by increasing nitric oxide bioactivity.
• Reduced circulating ghrelin levels may contribute to the pathobiology of atherosclerosis in these patients.